Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jean-Michel Gries"'
Autor:
Carl Mieczkowski, Xuejin Zhang, Dana Lee, Khanh Nguyen, Wei Lv, Yanling Wang, Yue Zhang, Jackie Way, Jean-Michel Gries
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTLarge-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review,
Externí odkaz:
https://doaj.org/article/2318ff49f7804c49989a29e5643f9352
Autor:
Jean-Michel Gries, Sudhakar M. Pai
Publikováno v:
Journal of clinical pharmacologyReferences. 62(1)
Autor:
Joanna C. Masters, Ahmed Salem, Mark Rogge, Gina Pastino, Jean-Michel Gries, William A. Clementi, Lorraine M. Rusch, Bruce I. Gaynes, Hartmut Derendorf, Sudhakar M. Pai, Ahmed A. Othman, Parag Kumar, Islam Younis, Douglas S. Greene
Publikováno v:
The Journal of Clinical Pharmacology
Journal of Clinical Pharmacology
Journal of Clinical Pharmacology
Autor:
Lourdes Martinez-Medina, Munevver Cinar, Jean-Michel Gries, Bassel F. El-Rayes, Leon Bernal-Mizrachi, Ganji Purnachandra Nagaraju
Publikováno v:
Blood. 138:3982-3982
Multiple myeloma (MM) is a heterogeneous malignant plasma cell disorder with complex molecular and genetic abnormalities. While current therapies have improved outcomes in MM, many patients relapse. Part of the development of the resistance to treatm
Autor:
Lourdes Martinez-Medina, Leon Bernal-Mizrachi, Neil R. Anthony, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Jean-Michel Gries, Munevver Cinar, Badri Vardarajan
Publikováno v:
Blood. 138:1588-1588
Multiple myeloma (MM) is a heterogeneous malignant plasma cell disorder with complex molecular and genetic abnormalities. Clonal evolution in MM is a hallmark of treatment failure. The origin of clonal evolution seems to result from the pressure indu
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 29:383-402
Significant arterio-venous differences in nicotine concentrations have been observed during and after cigarette smoking, nicotine nasal spray, and intravenous nicotine administration. In this paper we describe a novel mathematical method for estimati
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 28:343-362
For single-dose concentration–time data collected in clinical trials to be useful for explanatory pharmacokinetic (PK) or pharmacokinetic–pharmacodynamic (PK–PD) analyses, the following two assumptions on the data must hold: (i) the times of th
Autor:
Davide Verotta, Jean-Michel Gries
Publikováno v:
Journal of Biopharmaceutical Statistics. 10:383-398
In a frequently performed pharmacokinetics study, different subjects are given different doses of a drug. After each dose is given, drug concentrations are observed according to the same sampling design. The goal of the experiment is to obtain a repr
Autor:
Geertrui F. Vanhove, Jean Michel Gries, Kyungsoo Park, Helen Kastrissios, Ann C. Collier, Davide Verotta, Kathleen Squires, Terrence F. Blaschke, Lewis B. Sheiner
Publikováno v:
Scopus-Elsevier
We investigated the pharmacokinetics of zidovudine, zalcitabine, and saquinavir in AIDS Clinical Trial Group protocol 229. Patients received either saquinavir, zalcitabine, or a combination of both, together with zidovudine three times a day. Approxi
Publikováno v:
Clinical Pharmacology & Therapeutics. 61:70-82
Introduction This article reports a meta-analysis focused on the efficacy of zalcitabine and zidovudine alone or in combination as reported by three AIDS Clinical Trial Group trials. We analyzed the log CD4 count (LCD4) response to therapy up to 1 ye